Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3876 - TRUST: Phase II trial of induction chemotherapy (CT) with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC)


08 Oct 2016


Poster Display


Caterina Vivaldi


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


C. Vivaldi1, P. Buccianti2, G. Musettini3, F. Bergamo4, M.D. Rizzato4, A. Sainato5, A. Martignetti6, S. Lucchesi7, M. Franceschi2, C. Boso8, F. Pasqualetti5, L. Ginocchi7, F. Di Clemente9, A. Gonnelli5, L. Urbani10, S. Montrone5, I. Maretto11, F. Sidoti2, A. Falcone12, G. Masi1

Author affiliations

  • 1 Oncologia Medica Universitaria, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 2 U.o. Chirurgia Generale, Azienda Ospedaliero Universitaria Pisana, 56100 - Pisa/IT
  • 3 Medical Oncology, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 4 Dipartimento Di Oncologia Clinica E Sperimentale, Uoc Oncologia Medica 1, Istituto Oncologico Veneto IRCCS, Padova/IT
  • 5 U.o. Radioterapia, Azienda Ospedaliera Universitaria S.Chiara, Pisa/IT
  • 6 Dh Oncologico Val D'elsa, Azienda USL Toscana sud est, Siena/IT
  • 7 Department Of Oncology, Ospedale “F. Lotti” Pontedera, 56025 - Pontedera/IT
  • 8 Uoc Di Radioterapia, Istituto Oncologico Veneto IRCCS, Padova/IT
  • 9 Dh Oncologico Valdichiana, Azienda USL Toscana sud est, Siena/IT
  • 10 U.o. Chirurgia Generale, Azienda Ospedaliera Universitaria Pisana, 56100 - Pisa/IT
  • 11 Dipartimento Di Scienze Chirurgiche, Oncologiche E Gastroenterologiche, Clinica Chirurgica 1, Università di Padova, Padova/IT
  • 12 Oncologia Medica Universitaria, Azienda Ospedaliera Universitaria S.Chiara, Pisa/IT


Abstract 3876


Induction CT followed by CRT is a promising strategy in LARC. FOLFOXIRI + BV is an effective treatment in metastatic colorectal cancer.


This is a phase II single-arm trial. Patients (pts) with LARC at


We enrolled 48 pts: median age, 53 years (30-74); cT2/T3/T4, 4%/60%/36%; cN0/N + , 4%/96%; distance from anal verge 0-5/5-10/ > 10 cm, 56%/38%/6%. 46 pts completed induction therapy; 2 pts prematurely stopped treatment: 1 bowel perforation and sepsis resulting in death and 1 acute kidney injury recovered without sequelae. Main grade (G) 3/4 toxicities were: neutropenia (42%), febrile neutropenia (4.2%) and diarrhea (12.5%). After induction therapy 45 pts started CRT and 1 underwent surgery. After the first 13 pts, the protocol was amended and the schedule of capecitabine slightly modified (800 mg/m2/bid 5 days/week) due to an excessive rate of G3 hand-foot syndrome (23%) and proctitis (23%). After amendment, all pts completed CRT with acceptable toxicity: no G3-4 toxicities were reported, with the exception of proctitis (6.2%). After CRT 44 pts underwent surgery (1 died due to early progression after CRT): low anterior (89%) or abdomino-perineal (7%) resection. R0 resection was achieved in 98% resected pts. Early post-surgical complication rate was 32%, with a rate of 18% of anastomotic dehiscences (all solved). Pathologic complete response (pCR) rate was 36%. At a median follow up of 25.1 months, 11 pts experienced disease progression (3 local recurrences) and the estimated 2-year DFS is 78.8%.


Induction therapy with FOLFOXIRI + BV followed by CRT + BV is feasible, but a careful patient selection is needed because of the overall safety profile. Results in terms of pCR and preliminary DFS data are promising.

Clinical trial identification

EUDRACT 2011-003340-45 Start Date: 2012-02-23

Legal entity responsible for the study

Fondazione ARCO Onlus


trial promoted by Fondazione ARCO Onlus, bevacizumab provided by Roche


A. Falcone: Honoraria, advisory role, speakers' bureau: Amgen, Bayer, Merck Serono, Roche, Sanofi, Lilly. Research funding: Amgen, Bayer, Merck Serono, Roche, Sanofi. G. Masi: Honoraria: Roche, Merck Serono, Amgen, Sirtex. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings